N-Ethyl-1,5-diazacyclooctan | 13638-55-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-Ethyl-1,5-diazacyclooctan
• 英文别名: 1-Ethyl-octahydro-1,5-diazocin；1-Ethyl-1,5-diazacyclooctan；1-ethyl-[1,5]diazocane；1-Ethyl-1,5-diazocane
• CAS: 13638-55-6
• 化学式: C₈H₁₈N₂
• 分子量: 142.244
• InChiKey: YKGYLWUFJXIAFH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  N-乙基-1,3-丙二胺 、 1,3-二溴丙烷 以68%的产率得到
  参考文献：
  名称：

  MAJCHRZAK M.; KOTELKO A.; GURYN R., ACTA POL. PHARM. , 1975, 32, NO 2, 145-148

  摘要：

  DOI：

文献信息

• NOVEL COMPOUNDS, THEIR PREPARATION AND USE
  申请人：NEUROSEARCH A/S

  公开号：EP1406900A1

  公开（公告）日：2004-04-14
• SULFAMOYLBENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION
  申请人：Baruch S. Blumberg Institute

  公开号：EP2726459B1

  公开（公告）日：2019-09-11
• Inhibitors of p38
  申请人：Salituro Francesco

  公开号：US20070060572A1

  公开（公告）日：2007-03-15

  The present invention relates to inhibitors of p38, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.
• INHIBITORS OF p38
  申请人：Salituro Francesco

  公开号：US20090075981A1

  公开（公告）日：2009-03-19

  The present invention relates to inhibitors of p38, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.
• Inhibitors of DUX4 Induction for Regulation of Muscle Function
  申请人：Sonic Master Limited

  公开号：US20210361641A1

  公开（公告）日：2021-11-25

  Disclosed are methods and compositions for the treatment of facioscapulohumeral muscular dystrophy. In some cases, the methods and compositions involve the use of kinase inhibitors include Src, Syk, Abl, Tie, Flt, ErbB, Trk, PRKDC, and Yes families to repress DUX 4 expression in muscle cells. Further disclosed are methods and cell based assays for screening compounds for the treatment of facioscapulohumeral muscular dystrophy.